STICHTING ISALA KLINIEKEN

Their core work

Isala Klinieken is a large regional teaching hospital in Zwolle, the Netherlands, providing clinical research infrastructure and patient-facing trial capacity across cardiology, oncology, and interventional medicine. In EU-funded research, they contribute real-world clinical settings, patient cohorts, and multidisciplinary medical teams capable of running prospective studies. Their work spans from health systems research — evaluating cost-effectiveness and programme sustainability at scale — to advanced procedural interventions such as MR-guided focused ultrasound for cancer pain management. They bridge the gap between experimental medical technology and clinical adoption, bringing the hospital perspective on what it takes to translate a treatment into routine care.

What they specialise in

How they've shifted over time

In their first H2020 engagement (EU-CaRE, 2015–2019), Isala Klinieken operated as a coordinator in a health systems research mode — studying programme effectiveness and sustainability across European cardiac rehabilitation networks, with no specific procedural technology focus. By their second project (FURTHER, 2019–2025), the emphasis shifted entirely to an advanced interventional technology (MR-guided HIFU) applied to oncology, with explicit attention to economic viability and clinical translation. The trajectory suggests a deliberate move from programme-level health services research toward technology-enabled clinical innovation, particularly where new devices or procedures need rigorous hospital-based validation before entering routine practice.

Isala Klinieken is moving toward interventional oncology and medical device validation, making them a strong candidate for future consortia testing novel therapeutic technologies that require a credible clinical site with health economics capacity.

How they like to work

Isala has both led (EU-CaRE) and joined (FURTHER) projects, demonstrating flexibility across consortium roles. With 19 unique partners across 10 countries from just 2 projects, they engage in genuinely broad, multi-country consortia rather than repeating small familiar networks. This suggests they are comfortable operating within large, geographically distributed RIA consortia and can serve either as the coordinating clinical anchor or as one of several hospital partners.

Isala has connected with 19 distinct partners across 10 countries in only two projects, indicating they join diverse European networks rather than a closed group of recurring collaborators. Their network spans both health systems research partners and medical technology consortia, reflecting their dual clinical and research identity.

What sets them apart

Isala Klinieken brings something that universities and research institutes cannot: a fully operational large teaching hospital where patient recruitment, clinical procedures, and real-world outcome measurement happen under one roof in a non-academic setting. This makes them particularly valuable for trials that need ecological validity — results that reflect how a treatment actually performs in a regional hospital, not just a university medical centre. Their combination of RIA coordination experience, health economics competence, and willingness to engage with frontier medical technologies (HIFU) sets them apart from purely service-oriented hospital partners.

Highlights from their portfolio

• EU-CaRE
  Isala coordinated this pan-European cardiac rehabilitation study — rare for a regional hospital to hold the lead role in a multi-country RIA — and secured the largest share of their total EC funding (€912,851).
• FURTHER
  This ongoing project (2019–2025) positions Isala at the intersection of focused ultrasound technology, radiotherapy, and palliative oncology, a clinically and commercially high-interest area for medical device developers.